Pharsight

1. Drug name - ABILIFY MAINTENA KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10525057	OTSUKA PHARM CO LTD	Method of providing aripiprazole to patients having impaired CYP2D6 or CYP3A4 enzyme function	Mar, 2034 (11 years from now)

Drugs and Companies using ARIPIPRAZOLE ingredient

Treatment: Maintenance monotherapy treatment of bipolar 1 disorder; treatment of schizophrenia, with efficacy in treating acute episodes of schizophrenia; treatment of schizophrenia

Dosage: FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

Strength	Dosage	Availability
300MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
300MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG/VIAL	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription
400MG	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	Prescription

2. Drug name - ABRAXANE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9511046	ABRAXIS BIOSCIENCE	Methods of treating pancreatic cancer	Jan, 2034 (11 years from now)
US9511046 (Pediatric)	ABRAXIS BIOSCIENCE	Methods of treating pancreatic cancer	Jul, 2034 (11 years from now)

Drugs and Companies using PACLITAXEL ingredient

Treatment: Treatment of pancreatic cancer

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG/VIAL	POWDER;INTRAVENOUS	Prescription

3. Drug name - ADEMPAS

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10662188	BAYER HLTHCARE	Forms of methyl {4,6-diamino-2-[1 (2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl} methyl carbamate	Feb, 2034 (11 years from now)
US11203593	BAYER HLTHCARE	Forms of methyl {4,6-diamino-2-[1(2-fluorobenzyl)-1H-pyrazolo[3-4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate	Feb, 2034 (11 years from now)
EP2958914A1	BAYER HLTHCARE	Forms Of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-Yl]Pyrimidino-5-Yl}Methyl Carbamate	Feb, 2034 (11 years from now)
EP2958914B1	BAYER HLTHCARE	Forms Of Methyl {4,6-Diamino-2-[1-(2-Fluorobenzyl)-1H-Pyrazolo[3,4-B]Pyridino-3-Yl]Pyrimidino-5-Yl}Methyl Carbamate	Feb, 2034 (11 years from now)

Drugs and Companies using RIOCIGUAT ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
0.5MG	TABLET;ORAL	Prescription
1MG	TABLET;ORAL	Prescription
1.5MG	TABLET;ORAL	Prescription
2MG	TABLET;ORAL	Prescription
2.5MG	TABLET;ORAL	Prescription

4. Drug name - AIRDUO DIGIHALER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066957	TEVA PHARM	Dry powder inhaler	Oct, 2034 (12 years from now)
US9415008	TEVA PHARM	Dry powder inhaler	Oct, 2034 (12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE ingredient

Treatment: Treatment of asthma

Dosage: POWDER;INHALATION

Strength	Dosage	Availability
0.055MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.113MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription
0.232MG/INH;EQ 0.014MG BASE/INH	POWDER;INHALATION	Prescription

5. Drug name - ALKINDI SPRINKLE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9649280	ETON	Composition comprising hydrocortisone	May, 2034 (11 years from now)

Drugs and Companies using HYDROCORTISONE ingredient

Treatment: Treatment of adrenal insufficiency

Dosage: GRANULE;ORAL

Strength	Dosage	Availability
0.5MG	GRANULE;ORAL	Prescription
1MG	GRANULE;ORAL	Prescription
2MG	GRANULE;ORAL	Prescription
5MG	GRANULE;ORAL	Prescription

6. Drug name - ALUNBRIG

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9611283	TAKEDA PHARMS USA	Methods for inhibiting cell proliferation in ALK-driven cancers	Apr, 2034 (11 years from now)

Drugs and Companies using BRIGATINIB ingredient

Treatment: Treatment of anaplastic lymphoma kinase (alk)-positive metastatic non-small cell lung cancer (nsclc)

Dosage: TABLET;ORAL

Strength	Dosage	Availability
30MG	TABLET;ORAL	Prescription
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription

7. Drug name - ARIKAYCE KIT

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9566234	INSMED INC	Systems for treating pulmonary infections	Jan, 2034 (11 years from now)

Drugs and Companies using AMIKACIN SULFATE ingredient

Treatment: Treating mycobacterium avium complex (mac) lung disease in adults as part of a combination antibacterial drug regimen

Dosage: SUSPENSION, LIPOSOMAL;INHALATION

Strength	Dosage	Availability
EQ 590MG BASE/8.4ML	SUSPENSION, LIPOSOMAL;INHALATION	Prescription

8. Drug name - AUBAGIO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9186346	SANOFI AVENTIS US	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients	Feb, 2034 (11 years from now)
US9186346 (Pediatric)	SANOFI AVENTIS US	Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients	Aug, 2034 (11 years from now)

Drugs and Companies using TERIFLUNOMIDE ingredient

Treatment: Treatment of patients with relapsing forms of multiple sclerosis while managing the risk of teriflunomide and rosuvastatin interaction by limiting the rosuvastatin dose to no more than 10mg and/or administering about half the normal dose

Dosage: TABLET;ORAL

Strength	Dosage	Availability
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

9. Drug name - AUSTEDO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9296739 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)
US9814708 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)
US9233959 (Pediatric)	TEVA BRANDED PHARM	Formulations and pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)
US9550780 (Pediatric)	TEVA BRANDED PHARM	Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2	Mar, 2034 (11 years from now)

Drugs and Companies using DEUTETRABENAZINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
6MG	TABLET;ORAL	Prescription
9MG	TABLET;ORAL	Prescription
12MG	TABLET;ORAL	Prescription

10. Drug name - AYVAKIT

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9994575	BLUEPRINT MEDICINES	Compositions useful for treating disorders related to kit	Oct, 2034 (12 years from now)
US9200002	BLUEPRINT MEDICINES	Compositions useful for treating disorders related to KIT	Oct, 2034 (12 years from now)
US9944651	BLUEPRINT MEDICINES	Compositions useful for treating disorders related to kit	Oct, 2034 (12 years from now)
CN105658652A	BLUEPRINT MEDICINES	Composition For Treating Kit Disorders	Oct, 2034 (12 years from now)
CN105658652B	BLUEPRINT MEDICINES	Compound That Can Be Used To Treat A Disorder Associated With Kit	Oct, 2034 (12 years from now)
IN341186B	BLUEPRINT MEDICINES	Compositions Useful For Treating Disorders Related To Kit	Oct, 2034 (12 years from now)
IN201617009956A	BLUEPRINT MEDICINES	Compositions Useful For Treating Disorders Related To Kit	Oct, 2034 (12 years from now)
EP3409674A1	BLUEPRINT MEDICINES	Process For Preparing Compositions Useful For Treating Disorders Related To Kit	Oct, 2034 (12 years from now)
EP3409674B1	BLUEPRINT MEDICINES	Process For Preparing Compositions Useful For Treating Disorders Related To Kit	Oct, 2034 (12 years from now)
EP3057969B1	BLUEPRINT MEDICINES	Compositions Useful For Treating Disorders Related To Kit	Oct, 2034 (12 years from now)
EP3057969A1	BLUEPRINT MEDICINES	Compositions Useful For Treating Disorders Related To Kit	Oct, 2034 (12 years from now)

Drugs and Companies using AVAPRITINIB ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
25MG	TABLET;ORAL	Prescription
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription
300MG	TABLET;ORAL	Prescription

11. Drug name - BOSULIF

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11103497	PF PRISM CV	Treatment of imatinib resistant leukemia	Feb, 2034 (11 years from now)

Drugs and Companies using BOSUTINIB MONOHYDRATE ingredient

Treatment: A method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at 949t>c; a method for treating a bcrabl positive leukemia in a subject that is resistant to imatinib comprising administering to the subject a therapeutically effective amount of bosutinib, wherein the subject has a mutation in the bcrabl protein at f317l

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 100MG BASE	TABLET;ORAL	Prescription
EQ 400MG BASE	TABLET;ORAL	Prescription
EQ 500MG BASE	TABLET;ORAL	Prescription

12. Drug name - BRUKINSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10570139	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
US11142528	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
US9447106	BEIGENE	Substituted pyrazolo[1,5-a]pyrimidines as bruton's tyrosine kinase modulators	Apr, 2034 (11 years from now)
IN201503521P2	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Apr, 2034 (11 years from now)
IN370291B	BEIGENE	Fused Heterocyclic Compounds As Protein Kinase Inhibitors	Apr, 2034 (11 years from now)

Drugs and Companies using ZANUBRUTINIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
80MG	CAPSULE;ORAL	Prescription

13. Drug name - CAPLYTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9956227	INTRA-CELLULAR	Method for the treatment of residual symptoms of schizophrenia	Dec, 2034 (12 years from now)
US11026951	INTRA-CELLULAR	Methods of treating bipolar disorder	Dec, 2034 (12 years from now)
US10960009	INTRA-CELLULAR	Methods of treating schizophrenia and depression	Dec, 2034 (12 years from now)

Drugs and Companies using LUMATEPERONE TOSYLATE ingredient

Treatment: Treatment of schizophrenia with improvement in residual symptoms of schizophrenia; Treatment of bipolar i disorder, bipolar ii disorder, or bipolar depression; Treatment of schizophrenia

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 42MG BASE	CAPSULE;ORAL	Prescription

14. Drug name - CIBINQO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9545405	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)
US9035074	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)
CN105008362A	PFIZER	Pyrrolo [2, 3-D] Pyrimidine Derivative Used As James Related Kinase (As Jak) Inhibitor	Feb, 2034 (11 years from now)
CN105008362B	PFIZER	As Associated Janus Kinase (Jak) Inhibitor Of Pyrrolo [2 3-D] Pyrimidine Derivatives	Feb, 2034 (11 years from now)
CN107089985A	PFIZER	As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives	Feb, 2034 (11 years from now)
CN107089985B	PFIZER	As The Janus Kinase (Jak) Inhibitors Of Pyrrolo [2, 3-D] Pyrimidine Derivatives	Feb, 2034 (11 years from now)
IN201506803P1	PFIZER	Pyrrolo [2 3 D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)	Feb, 2034 (11 years from now)
IN329290B	PFIZER	Pyrrolo [2, 3, D]Pyrimidine Derivatives As Inhibitors Of Janus Related Kinases (Jak)	Feb, 2034 (11 years from now)
EP3290421A1	PFIZER	Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)	Feb, 2034 (11 years from now)
EP3290421B1	PFIZER	Combination Of Pyrrolo [2, 3 -D]Pyrimidine Derivatives With One Or More Additional Agents As Inhibitors Of Janus- Related Kinases (Jak)	Feb, 2034 (11 years from now)
EP2958921B1	PFIZER	Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)	Feb, 2034 (11 years from now)
EP2958921A1	PFIZER	Pyrrolo [2, 3 -D]Pyrimidine Derivatives As Inhibitors Of Janus Kinases (Jak)	Feb, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9549929	PFIZER	Pyrrolo[2,3-D]pyrimidine derivatives	Feb, 2034 (11 years from now)

Drugs and Companies using ABROCITINIB ingredient

Treatment: Treatment of adults with refractory, moderate-to-severe atopic dermatitis not adequately controlled with other systemic drug products or when use of those therapies is inadvisable

Dosage: TABLET;ORAL

Strength	Dosage	Availability
50MG	TABLET;ORAL	Prescription
100MG	TABLET;ORAL	Prescription
200MG	TABLET;ORAL	Prescription

15. Drug name - CLENPIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624879	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (11 years from now)
US11191753	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (11 years from now)
US9827231	FERRING PHARMS INC	Liquid pharmaceutical composition	Jun, 2034 (11 years from now)

Drugs and Companies using CITRIC ACID; MAGNESIUM OXIDE; SODIUM PICOSULFATE ingredient

Treatment: For cleansing of the colon as a preparation for colonoscopy; For cleansing the large intestine as a preparation for colonoscopy

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
12GM/BOT;3.5GM/BOT;10MG/BOT	SOLUTION;ORAL	Prescription

16. Drug name - CONTRAVE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10835527	NALPROPION	Compositions and methods for reducing major adverse cardiovascular events	Jul, 2034 (11 years from now)
US10231964	NALPROPION	Compositions and methods for weight loss in at risk patient populations	Jul, 2034 (11 years from now)
US10828294	NALPROPION	Compositions and methods for weight loss in at risk patient populations	Jul, 2034 (11 years from now)

Drugs and Companies using BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE ingredient

Treatment: For chronic weight management for treating overweight or obesity

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
90MG;8MG	TABLET, EXTENDED RELEASE;ORAL	Prescription

17. Drug name - COSELA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10966984	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)
US9487530	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)
US10085992	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)
US11040042	G1 THERAP	Transient protection of normal cells during chemotherapy	Mar, 2034 (11 years from now)

Drugs and Companies using TRILACICLIB DIHYDROCHLORIDE ingredient

Treatment: A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen for extensive-stage small cell lung cancer; a method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a topotecan-containing regimen for extensive- stage small cell lung cancer; A method to decrease the incidence of chemotherapy-induced myelosuppression in adult patients when administered prior to a carboplatin and etoposide-containing regimen for extensive-stage small cell lung cancer

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 300MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

18. Drug name - COTELLIC

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11087354	GENENTECH INC	Combination therapies	Jun, 2034 (11 years from now)

Drugs and Companies using COBIMETINIB FUMARATE ingredient

Treatment: Method of using cobimetinib for the treatment of melanoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 20MG BASE	TABLET;ORAL	Prescription

19. Drug name - DEXYCU KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10159683	EYEPOINT PHARMS	Use of sustained release dexamethasone in post-cataract surgery inflammation	May, 2034 (11 years from now)
US10028965	EYEPOINT PHARMS	Use of sustained release dexamethasone in post-cataract surgery inflammation	May, 2034 (11 years from now)
US10022502	EYEPOINT PHARMS	Dose guides for injection syringe	Jun, 2034 (11 years from now)

Drugs and Companies using DEXAMETHASONE ingredient

Treatment: Treatment of postoperative inflammation

Dosage: SUSPENSION;INTRAOCULAR

Strength	Dosage	Availability
9%	SUSPENSION;INTRAOCULAR	Prescription

20. Drug name - DIFICID

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808530	CUBIST PHARMS LLC	Composition of tiacumicin compounds	May, 2034 (11 years from now)
US9808530 (Pediatric)	CUBIST PHARMS LLC	Composition of tiacumicin compounds	Nov, 2034 (12 years from now)

Drugs and Companies using FIDAXOMICIN ingredient

Treatment: NA

Dosage: FOR SUSPENSION;ORAL

Strength	Dosage	Availability
40MG/ML	FOR SUSPENSION;ORAL	Prescription

21. Drug name - DILAUDID

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229	FRESENIUS KABI USA	Packaging system for oxygen-sensitive drugs	Mar, 2034 (11 years from now)

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: INJECTABLE;INJECTION

Strength	Dosage	Availability
0.2MG/ML	INJECTABLE;INJECTION	Prescription
1MG/ML	INJECTABLE;INJECTION	Prescription
2MG/ML	INJECTABLE;INJECTION	Prescription
4MG/ML	INJECTABLE;INJECTION	Discontinued
10MG/ML	INJECTABLE;INJECTION	Discontinued
250MG/VIAL	INJECTABLE;INJECTION	Discontinued

22. Drug name - DORYX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9295652	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (12 years from now)
US9511031	MAYNE PHARMA	Controlled release doxycycline	Oct, 2034 (12 years from now)
US9446057	MAYNE PHARMA	Controlled release doxycycline	Dec, 2034 (12 years from now)

Drugs and Companies using DOXYCYCLINE HYCLATE ingredient

Treatment: To treat or prevent infections caused by susceptible bacteria using delayed-release tablets consisting of doxycycline hyclate coated pellets in a tablet

Dosage: TABLET, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 80MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 100MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 150MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 200MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription
EQ 60MG BASE	TABLET, DELAYED RELEASE;ORAL	Discontinued
EQ 120MG BASE	TABLET, DELAYED RELEASE;ORAL	Prescription

23. Drug name - DURYSTA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9492316	ALLERGAN INC	Prostamide-containing intraocular implants and methods of use thereof	Oct, 2034 (12 years from now)
US9980974	ALLERGAN INC	Prostamide-containing intraocular implants and methods of use thereof	Oct, 2034 (12 years from now)

Drugs and Companies using BIMATOPROST ingredient

Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant

Dosage: IMPLANT;OPHTHALMIC

Strength	Dosage	Availability
10MCG	IMPLANT;OPHTHALMIC	Prescription

24. Drug name - EPCLUSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116783	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US10086011	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US9757406	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US11116783 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)
US10086011 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)
US9757406 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR ingredient

Treatment: For the treatment of hepatitis c

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
150MG;37.5MG/PACKET	PELLETS;ORAL	Prescription
200MG;50MG/PACKET	PELLETS;ORAL	Prescription

25. Drug name - EPIDIOLEX

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11154516	GW RES LTD	Use of cannabinoids in the treatment of epilepsy	Jun, 2034 (11 years from now)

Drugs and Companies using CANNABIDIOL ingredient

Treatment: Use for the treatment of seizures associated with dravet syndrome; use for the treatment of seizures associated with lennox-gastaut syndrome

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
100MG/ML	SOLUTION;ORAL	Prescription

26. Drug name - EPINEPHRINE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039728	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (11 years from now)
US10004700	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (11 years from now)
US9283197	BELCHER	More potent and less toxic formulations of epinephrine and methods of medical use	Aug, 2034 (11 years from now)

Drugs and Companies using EPINEPHRINE ingredient

Treatment: Increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; Emergency treatment of allergic reactions (type 1), including anaphylaxis; a method of treating allergic reaction, anaphylaxis, anaphylactic shock, or combination thereof by an injection of at least one dosage of the injectable liquid pharmaceutical; Emergency treatment of allergic reactions (type i), including anaphylaxis; increasing mean arterial blood pressure in adult patients with hypotension associated with septic shock; induction and maintenance of mydriasis during intraocular surgery

Dosage: SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
EQ 1MG BASE/ML (EQ 1MG BASE/ML)	SOLUTION;INTRAVENOUS, INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS	Prescription

27. Drug name - EVOMELA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10040872	ACROTECH	Alkylated cyclodextrin compositions and processes for preparing and using the same	Jan, 2034 (11 years from now)

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Treatment: NA

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 50MG BASE/VIAL	POWDER;INTRAVENOUS	Prescription

28. Drug name - EVZIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Jul, 2034 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
0.4MG/0.4ML (0.4MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

29. Drug name - EVZIO (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9517307	KALEO INC	Devices and methods for delivering opioid antagonists including formulations for naloxone	Jul, 2034 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of an auto injector to administer naloxone hcl

Dosage: SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS

Strength	Dosage	Availability
2MG/0.4ML (2MG/0.4ML)	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS	Discontinued

30. Drug name - EXONDYS 51

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9506058	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (11 years from now)
US10364431	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (11 years from now)
US10337003	SAREPTA THERAPS INC	Compositions for treating muscular dystrophy	Mar, 2034 (11 years from now)

Drugs and Companies using ETEPLIRSEN ingredient

Treatment: Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Restoring an mrna reading frame to induce dystrophin protein production in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping; Treatment of duchenne muscular dystrophy in patients having a mutation of the dmd gene that is amenable to exon 51 skipping

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
100MG/2ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription
500MG/10ML (50MG/ML)	SOLUTION;INTRAVENOUS	Prescription

31. Drug name - FIRDAPSE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10793893	CATALYST PHARMS	Methods of administering 3,4-diaminopyridine	Apr, 2034 (11 years from now)

Drugs and Companies using AMIFAMPRIDINE PHOSPHATE ingredient

Treatment: Method of treating lambert-eaton myasthenic syndrome with amifampridine

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 10MG BASE	TABLET;ORAL	Prescription

32. Drug name - FULVESTRANT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9833459	FRESENIUS KABI USA	Fulvestrant formulations	Feb, 2034 (11 years from now)
US10188663	FRESENIUS KABI USA	Fulvestrant formulations	Feb, 2034 (11 years from now)
US9271990	FRESENIUS KABI USA	Fulvestrant formulations	May, 2034 (11 years from now)

Drugs and Companies using FULVESTRANT ingredient

Treatment: Treatment of hormone receptor positive advanced breast cancer in postmenopausal women

Dosage: SOLUTION;INTRAMUSCULAR

Strength	Dosage	Availability
250MG/5ML (50MG/ML)	SOLUTION;INTRAMUSCULAR	Prescription

33. Drug name - GANZYK-RTU

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9486530	EXELA PHARMA	Ganciclovir compositions and related methods	Sep, 2034 (11 years from now)

Drugs and Companies using GANCICLOVIR ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
500MG/250ML (2MG/ML)	SOLUTION;INTRAVENOUS	Prescription

34. Drug name - GIAPREZA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11096983	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (12 years from now)
US10493124	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (12 years from now)
US9220745	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (12 years from now)
US10028995	LA JOLLA PHARMA	Angiotensin II alone or in combination for the treatment of hypotension	Dec, 2034 (12 years from now)

Drugs and Companies using ANGIOTENSIN II ACETATE ingredient

Treatment: Treating distributive shock with angiotensin ii; treating septic shock with angiotensin ii; Treating low blood pressure with angiotensin ii at an initial rate of about 20 ng/kg/min and titrating down to achieve and/or maintain a map of about 65 mm hg or above; Maintaining mean arterial pressure of about 65 mmhg or higher with angiotensin ii in shock patients treated with catecholamines and reducing catecholamine use; treating high output shock with angiotensin ii by increasing mean arterial pressure in patients treated with catecholamines and reducing catecholamine use; Maintaining mean arterial pressure of about 65 mmhg or above with about 1 ng/kg/min to about 40 ng/kg/min angiotensin ii in hypotensive patients treated with vasopressin or a vasopressin analogue and reducing vasopressin or vasopressin analogue use

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
EQ 0.5MG BASE/ML (EQ 0.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 2.5MG BASE/ML (EQ 2.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Prescription
EQ 5MG BASE/2ML (EQ 2.5MG BASE/ML)	SOLUTION;INTRAVENOUS	Discontinued

35. Drug name - GIVLAARI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10119143	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Oct, 2034 (12 years from now)
US11028392	ALNYLAM PHARMS INC	Compositions and methods for inhibiting expression of the ALAS1 gene	Oct, 2034 (12 years from now)
CN105980559A	ALNYLAM PHARMS INC	Composition And Method For Inhibition Of Alas1 Gene Expression	Oct, 2034 (12 years from now)
CN105980559B	ALNYLAM PHARMS INC	Composition And Method For Inhibiting Alas1 Gene Expression	Oct, 2034 (12 years from now)
IN201647014609A	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Oct, 2034 (12 years from now)
IN392668B	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Oct, 2034 (12 years from now)
EP3052628A1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Oct, 2034 (12 years from now)
EP3052628B1	ALNYLAM PHARMS INC	Compositions And Methods For Inhibiting Expression Of The Alas1 Gene	Oct, 2034 (12 years from now)

Drugs and Companies using GIVOSIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 189MG BASE/ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

36. Drug name - GLYXAMBI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN ingredient

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG;5MG	TABLET;ORAL	Prescription
25MG;5MG	TABLET;ORAL	Prescription

37. Drug name - GOCOVRI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10646456	ADAMAS PHARMA	Methods of administering amantadine	Jun, 2034 (11 years from now)
US10154971	ADAMAS PHARMA	Methods of administering amantadine	Dec, 2034 (12 years from now)

Drugs and Companies using AMANTADINE HYDROCHLORIDE ingredient

Treatment: Treatment of dyskinesia, decreasing off time, and increasing on time without troublesome dyskinesia in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications; Treatment of dyskinesia and decreasing off time in patients with parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 68.5MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
EQ 137MG BASE	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

38. Drug name - HARVONI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10039779	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
CN105748499A	GILEAD SCIENCES INC	Coupling Preparation Of Two Antiviral Compounds	Jan, 2034 (11 years from now)
CN105748499B	GILEAD SCIENCES INC	A Combined Preparation Of Two Antiviral Compounds	Jan, 2034 (11 years from now)
EP2950786B1	GILEAD SCIENCES INC	Combination Formulation Of Two Antiviral Compounds	Jan, 2034 (11 years from now)
EP2950786A1	GILEAD SCIENCES INC	Combination Formulation Of Two Antiviral Compounds	Jan, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10039779 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)

Drugs and Companies using LEDIPASVIR; SOFOSBUVIR ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
45MG;200MG	TABLET;ORAL	Prescription
90MG;400MG	TABLET;ORAL	Prescription

39. Drug name - HETLIOZ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910	VANDA PHARMS INC	Treatment of circadian rhythm disorders	May, 2034 (11 years from now)
US10610511	VANDA PHARMS INC	Method of treatment	Oct, 2034 (12 years from now)
US11141400	VANDA PHARMS INC	Method of treatment	Oct, 2034 (12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of non-24-hour sleep-wake disorder by avoiding the use of tasimelteon in combination with rifampin; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food; treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; Treatment of non-24 hour sleep-wake disorder by avoiding the administration of tasimelteon with food; treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
20MG	CAPSULE;ORAL	Prescription

40. Drug name - HETLIOZ LQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9730910	VANDA PHARMS INC	Treatment of circadian rhythm disorders	May, 2034 (11 years from now)
US10610511	VANDA PHARMS INC	Method of treatment	Oct, 2034 (12 years from now)
US11141400	VANDA PHARMS INC	Method of treatment	Oct, 2034 (12 years from now)

Drugs and Companies using TASIMELTEON ingredient

Treatment: Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the use of tasimelteon with rifampin; Treatment of nighttime sleep disturbances in smith-magenis syndrome by avoiding the administration of tasimelteon with food

Dosage: SUSPENSION;ORAL

Strength	Dosage	Availability
4MG/ML	SUSPENSION;ORAL	Prescription

41. Drug name - IBRANCE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10723730	PFIZER	Solid forms of a selective CDK4/6 inhibitor	Feb, 2034 (11 years from now)
EP3431475A1	PFIZER	Solid Forms Of A Selective Cdk4/6 Inhibitor	Feb, 2034 (11 years from now)
EP3431475B1	PFIZER	Solid Forms Of A Selective Cdk4/6 Inhibitor	Feb, 2034 (11 years from now)
EP2958916A1	PFIZER	Solid Forms Of A Selective Cdk4/6 Inhibitor	Feb, 2034 (11 years from now)
EP2958916B1	PFIZER	Solid Forms Of A Selective Cdk4/6 Inhibitor	Feb, 2034 (11 years from now)

Drugs and Companies using PALBOCICLIB ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
75MG	CAPSULE;ORAL	Prescription
100MG	CAPSULE;ORAL	Prescription
125MG	CAPSULE;ORAL	Prescription

42. Drug name - IDHIFA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9738625	CELGENE CORP	Therapeutically active compounds and their methods of use	Aug, 2034 (11 years from now)
US10093654	CELGENE CORP	Therapeutically active compounds and their methods of use	Aug, 2034 (11 years from now)
US9732062	CELGENE CORP	Therapeutically active compounds and their methods of use	Sep, 2034 (11 years from now)
EP3566706B1	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Aug, 2034 (11 years from now)
EP3566706A1	CELGENE CORP	Therapeutically Active Compounds And Their Methods Of Use	Aug, 2034 (11 years from now)

Drugs and Companies using ENASIDENIB MESYLATE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 50MG BASE	TABLET;ORAL	Prescription
EQ 100MG BASE	TABLET;ORAL	Prescription

43. Drug name - IMBRUVICA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10463668	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Oct, 2034 (12 years from now)
US10695350	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Oct, 2034 (12 years from now)
US9795604	PHARMACYCLICS INC	Methods of treating and preventing graft versus host disease	Oct, 2034 (12 years from now)

Drugs and Companies using IBRUTINIB ingredient

Treatment: Treatment of refractory chronic graft-versus-host disease; Treatment of chronic graft versus host disease refractory to systemic therapy; Treatment of adult patients with chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy; treatment of adult patients with cyclosporin-resistant, steroid-dependent/refractory, or steroid resistant chronic graft-versus-host disease (cgvhd) after failure of one or more lines of systemic therapy

Dosage: TABLET;ORAL

Strength	Dosage	Availability
140MG	TABLET;ORAL	Prescription
280MG	TABLET;ORAL	Prescription
420MG	TABLET;ORAL	Prescription
560MG	TABLET;ORAL	Prescription

44. Drug name - IMCIVREE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11129869	RHYTHM	Pharmaceutical compositions	Jul, 2034 (11 years from now)

Drugs and Companies using SETMELANOTIDE ACETATE ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 10MG/ML BASE (EQ 10MG/ML BASE)	SOLUTION;SUBCUTANEOUS	Prescription

45. Drug name - INOMAX

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9279794	MALLINCKRODT HOSP	Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide	Feb, 2034 (11 years from now)
US9279794 (Pediatric)	MALLINCKRODT HOSP	Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide	Aug, 2034 (11 years from now)

Drugs and Companies using NITRIC OXIDE ingredient

Treatment: A method of providing nitric oxide therapy to a patient by compensating long-term sensitivity drift of electrochemical gas sensors used in systems for delivering therapeutic nitric oxide to a patient

Dosage: GAS;INHALATION

Strength	Dosage	Availability
100PPM	GAS;INHALATION	Discontinued
800PPM	GAS;INHALATION	Prescription

46. Drug name - JADENU

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9283209	NOVARTIS PHARMS CORP	Oral formulations of deferasirox	Nov, 2034 (12 years from now)
CN105025886B	NOVARTIS PHARMS CORP	Oral Preparation Of Deferasirox (Deferasirox)	Mar, 2034 (11 years from now)
CN105025886A	NOVARTIS PHARMS CORP	Oral Preparation Of Deferasirox (Deferasirox)	Mar, 2034 (11 years from now)
EP3124018A1	NOVARTIS PHARMS CORP	Oral Formulations Of Deferasirox	Mar, 2034 (11 years from now)
EP2964202A1	NOVARTIS PHARMS CORP	Oral Formulations Of Deferasirox	Mar, 2034 (11 years from now)
EP2964202B1	NOVARTIS PHARMS CORP	Oral Formulations Of Deferasirox	Mar, 2034 (11 years from now)
EP3124018B1	NOVARTIS PHARMS CORP	Oral Formulations Of Deferasirox	Mar, 2034 (11 years from now)

Drugs and Companies using DEFERASIROX ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
90MG	TABLET;ORAL	Prescription
180MG	TABLET;ORAL	Prescription
360MG	TABLET;ORAL	Prescription

47. Drug name - JARDIANCE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949997	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	May, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (30 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of reducing the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease by once daily administration of 10 mg or 25 mg of empagliflozin; method for reducing the risk of cardiovascular death plus hospitalization for heart failure in adults with type 2 diabetes mellitus, heart failure and reduced ejection fraction by once daily administration of empagliflozin

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
25MG	TABLET;ORAL	Prescription

48. Drug name - JUBLIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10828293	BAUSCH	Anti-infective methods, compositions, and devices	Oct, 2034 (12 years from now)
US10342875	BAUSCH	Stabilized efinaconazole compositions	Oct, 2034 (12 years from now)
US10864274	BAUSCH	Stabilized efinaconazole formulations	Oct, 2034 (12 years from now)
US9662394	BAUSCH	Stabilized efinaconazole compositions	Oct, 2034 (12 years from now)

Drugs and Companies using EFINACONAZOLE ingredient

Treatment: Antimycotic uses, specifically treatment of onychomycosis; topical treatment of the toenail(s) due to trichophyton rubrum and trichophyton mentagrophytes

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
10%	SOLUTION;TOPICAL	Prescription

49. Drug name - KLOXXADO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10973814	HIKMA	Liquid naloxone spray	Aug, 2034 (11 years from now)
US10722510	HIKMA	Liquid naloxone spray	Aug, 2034 (11 years from now)

Drugs and Companies using NALOXONE HYDROCHLORIDE ingredient

Treatment: Use of naloxone for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression, for adult and pediatric patients

Dosage: SPRAY;NASAL

Strength	Dosage	Availability
8MG/SPRAY	SPRAY;NASAL	Prescription

50. Drug name - LEQVIO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10125369	NOVARTIS	PCSK9 iRNA compositions and methods of use thereof	Aug, 2034 (11 years from now)

Drugs and Companies using INCLISIRAN SODIUM ingredient

Treatment: NA

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 284MG BASE/1.5ML (EQ 189MG BASE/ML)	SOLUTION;SUBCUTANEOUS	Prescription

51. Drug name - LILETTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028858	MEDICINES360	Intrauterine systems, IUD insertion devices, and related methods and kits therefor	Mar, 2034 (11 years from now)

Drugs and Companies using LEVONORGESTREL ingredient

Treatment: A method for prevention of pregnancy

Dosage: INTRAUTERINE DEVICE;INTRAUTERINE

Strength	Dosage	Availability
52MG	INTRAUTERINE DEVICE;INTRAUTERINE	Prescription

52. Drug name - LONSURF

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10457666	TAIHO ONCOLOGY	Stable crystal form of tipiracil hydrochloride and crystallization method for the same	Jun, 2034 (11 years from now)
US9527833	TAIHO ONCOLOGY	Stable crystal form of tipiracil hydrochloride and crystallization method for the same	Jun, 2034 (11 years from now)
EP3012255A4	TAIHO ONCOLOGY	Stabilized Crystal Of Tipiracil Hydrochloride, And Crystallization Method For Same	Jun, 2034 (11 years from now)
EP3012255B1	TAIHO ONCOLOGY	Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same	Jun, 2034 (11 years from now)
EP3012255A1	TAIHO ONCOLOGY	Stable Crystal Form Of Tipiracil Hydrochloride And Crystallization Method For The Same	Jun, 2034 (11 years from now)

Drugs and Companies using TIPIRACIL HYDROCHLORIDE; TRIFLURIDINE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 6.14MG BASE;15MG	TABLET;ORAL	Prescription
EQ 8.19MG BASE;20MG	TABLET;ORAL	Prescription

53. Drug name - LOREEV XR

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8999393	ALMATICA	Sustained release formulations of lorazepam	Jan, 2034 (11 years from now)

Drugs and Companies using LORAZEPAM ingredient

Treatment: Once daily treatment of anxiety disorder in adults

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
1MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
1.5MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
2MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription
3MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

54. Drug name - LUZU

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980931	BAUSCH	Method of evaluating pharmaceutical preparation containing luliconazole and index substance	Apr, 2034 (11 years from now)

Drugs and Companies using LULICONAZOLE ingredient

Treatment: NA

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
1%	CREAM;TOPICAL	Prescription

55. Drug name - MAKENA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9789257	COVIS	Needle assisted injection device having reduced trigger force	Feb, 2034 (11 years from now)

Drugs and Companies using HYDROXYPROGESTERONE CAPROATE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAMUSCULAR; SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
1250MG/5ML (250MG/ML)	SOLUTION;INTRAMUSCULAR	Prescription
250MG/ML (250MG/ML)	SOLUTION;INTRAMUSCULAR	Prescription
275MG/1.1ML (250MG/ML)	SOLUTION;SUBCUTANEOUS	Prescription

56. Drug name - MAVYRET

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10286029	ABBVIE INC	Method for treating HCV	Mar, 2034 (11 years from now)
US10286029 (Pediatric)	ABBVIE INC	Method for treating HCV	Sep, 2034 (11 years from now)

Drugs and Companies using GLECAPREVIR; PIBRENTASVIR ingredient

Treatment: Treatment of chronic hepatitis c virus (hcv) genotype 1, 2, 3, 4, 5, or 6 in adult and pediatric patients 12 years and older or weighing at least 45 kg

Dosage: PELLETS;ORAL

Strength	Dosage	Availability
50MG;20MG/PACKET	PELLETS;ORAL	Prescription

57. Drug name - MORPHINE SULFATE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248229	FRESENIUS KABI USA	Packaging system for oxygen-sensitive drugs	Mar, 2034 (11 years from now)
US9192608	FRESENIUS KABI USA	Morphine formulations	Mar, 2034 (11 years from now)
US9072781	FRESENIUS KABI USA	Morphine formulations	Mar, 2034 (11 years from now)

Drugs and Companies using MORPHINE SULFATE ingredient

Treatment: Management of chronic pain in patients requiring opioid analgesia; treatment of pain

Dosage: SOLUTION;INTRAMUSCULAR, INTRAVENOUS

Strength	Dosage	Availability
2MG/ML (2MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
4MG/ML (4MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
5MG/ML (5MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
8MG/ML (8MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription
10MG/ML (10MG/ML)	SOLUTION;INTRAMUSCULAR, INTRAVENOUS	Prescription

58. Drug name - NATESTO

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11090312	ACERUS	Methods of treating hypogonadism with transnasal testerosterone bio-adhesive gel formulations in male with allergic rhinitis, and methods for preventing an allergic rhinitis event	Mar, 2034 (11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: Nasal administration of a testosterone gel to a patient to treat the patient for a condition associated with a deficiency or absence of endogenous testosterone

Dosage: GEL, METERED;NASAL

Strength	Dosage	Availability
5.5MG/0.122GM ACTUATION	GEL, METERED;NASAL	Prescription

59. Drug name - OMIDRIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9066856 (Pediatric)	RAYNER SURGICAL	Stable preservative-free mydriatic and anti-inflammatory solutions for injection	Apr, 2034 (11 years from now)
US9486406 (Pediatric)	RAYNER SURGICAL	Stable preservative-free mydriatic and anti-inflammatory solutions for injection	Apr, 2034 (11 years from now)

Drugs and Companies using KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE ingredient

Treatment: NA

Dosage: SOLUTION;IRRIGATION

Strength	Dosage	Availability
EQ 0.3% BASE;EQ 1% BASE	SOLUTION;IRRIGATION	Prescription

60. Drug name - ONZETRA XSAIL

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614	CURRAX	Nasal delivery devices	Oct, 2034 (12 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Treatment: NA

Dosage: POWDER;NASAL

Strength	Dosage	Availability
EQ 11MG BASE	POWDER;NASAL	Prescription

61. Drug name - ORIAHNN (COPACKAGED)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881659	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)
US11045470	ABBVIE INC	Methods of treating heavy menstrual bleeding	Mar, 2034 (11 years from now)

Drugs and Companies using ELAGOLIX SODIUM,ESTRADIOL,NORETHINDRONE ACETATE; ELAGOLIX SODIUM ingredient

Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids)

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
EQ 300MG BASE,1MG,0.5MG; EQ 300MG BASE	CAPSULE;ORAL	Prescription

62. Drug name - OTEZLA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10092541	AMGEN INC	Methods for the treatment of diseases ameliorated by PDE4 inhibition using dosage titration of apremilast	May, 2034 (11 years from now)
US9872854	AMGEN INC	Methods for the treatment of psoriatic arthritis using apremilast	May, 2034 (11 years from now)

Drugs and Companies using APREMILAST ingredient

Treatment: Treatment of psoriasis using a dosage titration schedule; treatment of adult patients with oral ulcers associated with behcet's disease using a dosage titration schedule; Treatment of psoriatic arthritis using a dosage titration schedule; treatment of psoriatic arthritis with apremilast using a dosage titration schedule and a second active agent

Dosage: TABLET;ORAL

Strength	Dosage	Availability
10MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription
30MG	TABLET;ORAL	Prescription

63. Drug name - OXBRYTA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9248199	GLOBAL BLOOD THERAPS	1:1 adducts of sickle hemoglobin	Jan, 2034 (11 years from now)

Drugs and Companies using VOXELOTOR ingredient

Treatment: Treatment of sickle cell disease by administering voxelotor, as recited in claim 1; treatment of sickle cell disease by administering voxelotor, as recited in claim 2

Dosage: TABLET;ORAL

Strength	Dosage	Availability
500MG	TABLET;ORAL	Prescription

64. Drug name - OXLUMO

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9828606	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (12 years from now)
US10465195	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (12 years from now)
US10487330	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (12 years from now)
US11060093	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (12 years from now)
EP3087184B1	ALNYLAM PHARMS INC	Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna	Dec, 2034 (12 years from now)
EP3087184A4	ALNYLAM PHARMS INC	Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna	Dec, 2034 (12 years from now)
EP3087184A1	ALNYLAM PHARMS INC	Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna	Dec, 2034 (12 years from now)
EP3581654A1	ALNYLAM PHARMS INC	Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna	Dec, 2034 (12 years from now)
EP3581654B1	ALNYLAM PHARMS INC	Methods And Compositions For The Specific Inhibition Of Glycolate Oxidase (Hao1) By Double-Stranded Rna	Dec, 2034 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10435692	ALNYLAM PHARMS INC	Methods and compositions for the specific inhibition of glycolate oxidase (HAO1) by double-stranded RNA	Dec, 2034 (12 years from now)

Drugs and Companies using LUMASIRAN SODIUM ingredient

Treatment: Treatment of primary hyperoxaluria type 1 (ph1)

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
EQ 94.5MG/0.5ML BASE (EQ 94.5MG/0.5ML BASE)	SOLUTION;SUBCUTANEOUS	Prescription

65. Drug name - PARSABIV

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10344765	KAI PHARMS INC	Stable liquid formulation of AMG 416 (etelcalcetide)	Jun, 2034 (11 years from now)
US9820938	KAI PHARMS INC	Stable liquid formulation of AMG 416 (etelcalcetide)	Jun, 2034 (11 years from now)
US11162500	KAI PHARMS INC	Stable liquid formulation of AMG 416 (etelcalcetide)	Jun, 2034 (11 years from now)

Drugs and Companies using ETELCALCETIDE ingredient

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

Strength	Dosage	Availability
2.5MG/0.5ML (2.5MG/0.5ML)	SOLUTION;INTRAVENOUS	Prescription
5MG/ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription
10MG/2ML (5MG/ML)	SOLUTION;INTRAVENOUS	Prescription

66. Drug name - PROCYSBI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173851	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9233077	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9173851 (Pediatric)	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (12 years from now)
US9233077 (Pediatric)	HORIZON	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (12 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: NA

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 25MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription
EQ 75MG BASE	CAPSULE, DELAYED RELEASE;ORAL	Prescription

67. Drug name - PROCYSBI

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9173851	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9233077	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Jun, 2034 (11 years from now)
US9173851 (Pediatric)	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (12 years from now)
US9233077 (Pediatric)	HORIZON PHARMA USA	Delayed release cysteamine bead formulation, and methods of making and using same	Dec, 2034 (12 years from now)

Drugs and Companies using CYSTEAMINE BITARTRATE ingredient

Treatment: NA

Dosage: GRANULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
EQ 75MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription
EQ 300MG BASE/PACKET	GRANULE, DELAYED RELEASE;ORAL	Prescription

68. Drug name - RAYALDEE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10357502	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)
US11253528	EIRGEN	Stabilized modified release Vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)
US9861644	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)
US10300078	EIRGEN	Stabilized modified release vitamin D formulation and method of administering same	Mar, 2034 (11 years from now)

Drugs and Companies using CALCIFEDIOL ingredient

Treatment: NA

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
0.03MG	CAPSULE, EXTENDED RELEASE;ORAL	Prescription

69. Drug name - RESTASIS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9676525	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	Feb, 2034 (11 years from now)
US9669974	ALLERGAN	Protective cap for a dispenser, and discharge device for discharging pharmaceutical and/or cosmetical liquids	May, 2034 (11 years from now)

Drugs and Companies using CYCLOSPORINE ingredient

Treatment: NA

Dosage: EMULSION;OPHTHALMIC

Strength	Dosage	Availability
0.05%	EMULSION;OPHTHALMIC	Prescription

70. Drug name - RHOPRESSA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9931336	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US10588901	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US9415043	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
CN109528721A	AERIE PHARMS INC	Combination Therapy	Mar, 2034 (11 years from now)
CN109528721B	AERIE PHARMS INC	Combination Therapy	Mar, 2034 (11 years from now)
EP2976080B1	AERIE PHARMS INC	Conjugates Of Isoquinoline Compounds And Prostaglandins	Mar, 2034 (11 years from now)
EP2976080A1	AERIE PHARMS INC	Conjugates Of Isoquinoline Compounds And Prostaglandins	Mar, 2034 (11 years from now)
EP3461484B1	AERIE PHARMS INC	Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders	Mar, 2034 (11 years from now)
EP3461484B9	AERIE PHARMS INC	Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders	Mar, 2034 (11 years from now)
EP3461484A1	AERIE PHARMS INC	Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders	Mar, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11185538	AERIE PHARMS INC	Compositions for treating glaucoma or reducing intraocular pressure	Mar, 2034 (11 years from now)

Drugs and Companies using NETARSUDIL MESYLATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
EQ 0.02% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

71. Drug name - ROCKLATAN

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9993470	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US9931336	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US10588901	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US9415043	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
CN109528721A	AERIE PHARMS INC	Combination Therapy	Mar, 2034 (11 years from now)
CN109528721B	AERIE PHARMS INC	Combination Therapy	Mar, 2034 (11 years from now)
EP2976080B1	AERIE PHARMS INC	Conjugates Of Isoquinoline Compounds And Prostaglandins	Mar, 2034 (11 years from now)
EP2976080A1	AERIE PHARMS INC	Conjugates Of Isoquinoline Compounds And Prostaglandins	Mar, 2034 (11 years from now)
EP3461484B1	AERIE PHARMS INC	Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders	Mar, 2034 (11 years from now)
EP3461484B9	AERIE PHARMS INC	Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders	Mar, 2034 (11 years from now)
EP3461484A1	AERIE PHARMS INC	Dimesylate Salts Of 4-(3-Amino-1-(Isoquinolin-6-Ylamino)-1-Oxopropan-2-Yl)Benzyl, Their Combinations With Prostaglandins And The Use Thereof In The Treatment Of Ocular Disorders	Mar, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11197853	AERIE PHARMS INC	Combination therapy	Mar, 2034 (11 years from now)
US11185538	AERIE PHARMS INC	Compositions for treating glaucoma or reducing intraocular pressure	Mar, 2034 (11 years from now)

Drugs and Companies using LATANOPROST; NETARSUDIL DIMESYLATE ingredient

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

Strength	Dosage	Availability
0.005%;EQ 0.02% BASE	SOLUTION/DROPS;OPHTHALMIC	Prescription

72. Drug name - RYALTRIS

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10758550	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10765686	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US10646500	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10548907	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10016443	GLENMARK SPECIALTY	Treatment of allergic rhinitis using a combination of mometasone and olopatadine	Sep, 2034 (11 years from now)
US10517880	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9750754	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9078923	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9937189	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US10376526	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US9370483	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)
US10561672	GLENMARK SPECIALTY	Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine	Sep, 2034 (11 years from now)

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Treatment: Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient; Method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway; Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.025MG/SPRAY;0.665MG/SPRAY	SPRAY, METERED;NASAL	Prescription

73. Drug name - RYBELSUS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10278923	NOVO	Oral dosing of GLP-1 compounds	May, 2034 (11 years from now)

Drugs and Companies using SEMAGLUTIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription
7MG	TABLET;ORAL	Prescription
14MG	TABLET;ORAL	Prescription

74. Drug name - SINUVA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10406332	INTERSECT ENT INC	Systems, devices, and method for treating a sinus condition	Mar, 2034 (11 years from now)
US10232152	INTERSECT ENT INC	Systems, devices, and method for treating a sinus condition	Nov, 2034 (12 years from now)

Drugs and Companies using MOMETASONE FUROATE ingredient

Treatment: Treatment of nasal polyps in patients >=18 years of age who have had ethmoid sinus surgery using a corticosteroid-eluting (mometasone furoate) implant

Dosage: IMPLANT;IMPLANTATION

Strength	Dosage	Availability
1.35MG	IMPLANT;IMPLANTATION	Prescription

75. Drug name - SOOLANTRA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9089587	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)
US10206939	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)
US9782425	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)
US9233117	GALDERMA LABS LP	Treatment of inflammatory lesions of rosacea with ivermectin	Mar, 2034 (11 years from now)
US9233118	GALDERMA LABS LP	Treatment of papulopustular rosacea with ivermectin	Mar, 2034 (11 years from now)

Drugs and Companies using IVERMECTIN ingredient

Treatment: Treatment of inflammatory lesions of rosacea.

Dosage: CREAM;TOPICAL

Strength	Dosage	Availability
1%	CREAM;TOPICAL	Prescription

76. Drug name - SOTYLIZE

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206895	ARBOR PHARMS LLC	Sotalol compositions and uses of the same	Apr, 2034 (11 years from now)
US11013703	ARBOR PHARMS LLC	Sotalol compositions and uses of the same	Apr, 2034 (11 years from now)

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening

Dosage: SOLUTION;ORAL

Strength	Dosage	Availability
5MG/ML (5MG/ML)	SOLUTION;ORAL	Prescription

77. Drug name - SPINRAZA

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9926559	BIOGEN IDEC	Compositions and methods for modulation of SMN2 splicing in a subject	Jan, 2034 (11 years from now)

Drugs and Companies using NUSINERSEN SODIUM ingredient

Treatment: Treatment of spinal muscular atrophy

Dosage: SOLUTION;INTRATHECAL

Strength	Dosage	Availability
EQ 12MG BASE/5ML (EQ 2.4MG BASE/ML)	SOLUTION;INTRATHECAL	Prescription

78. Drug name - SPRITAM

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9339489	APRECIA PHARMS	Rapid disperse dosage form containing levetiracetam	Mar, 2034 (11 years from now)
US9669009	APRECIA PHARMS	Rapid disperse dosage form containing levetiracetam	Mar, 2034 (11 years from now)
US11160786	APRECIA PHARMS	Rapid disperse dosage form	Mar, 2034 (11 years from now)

Drugs and Companies using LEVETIRACETAM ingredient

Treatment: Method of administering levetiracetam; Method of administering levetiracetam under fasted conditions; method of administering levetiracetam; method of administering levetiracetam under fed conditions

Dosage: TABLET, FOR SUSPENSION;ORAL

Strength	Dosage	Availability
1GM	TABLET, FOR SUSPENSION;ORAL	Prescription
250MG	TABLET, FOR SUSPENSION;ORAL	Prescription
500MG	TABLET, FOR SUSPENSION;ORAL	Prescription
750MG	TABLET, FOR SUSPENSION;ORAL	Prescription

79. Drug name - SYNJARDY

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin; Method of treating type 2 diabetes mellitus in a patent with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr<30 ml/min/1.73 m2

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG;1GM	TABLET;ORAL	Prescription
5MG;500MG	TABLET;ORAL	Prescription
12.5MG;1GM	TABLET;ORAL	Prescription
12.5MG;500MG	TABLET;ORAL	Prescription

80. Drug name - SYNJARDY XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
12.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
25MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

81. Drug name - TALICIA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9050263	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)
US9603806	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)
US9498445	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)
US11135172	REDHILL	Rifabutin-based compositions and methods for treating Helicobacter pylori infection	Feb, 2034 (11 years from now)
US10238606	REDHILL	Pharmaceutical compositions for the treatment of Helicobacter pylori	Feb, 2034 (11 years from now)

Drugs and Companies using AMOXICILLIN; OMEPRAZOLE MAGNESIUM; RIFABUTIN ingredient

Treatment: Treatment of h. pylori infection in adults

Dosage: CAPSULE, DELAYED RELEASE;ORAL

Strength	Dosage	Availability
250MG;EQ 10MG BASE;12.5MG	CAPSULE, DELAYED RELEASE;ORAL	Prescription

82. Drug name - TAZVERIK

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9688665	EPIZYME INC	Methods of treating cancer	Aug, 2034 (11 years from now)

Drugs and Companies using TAZEMETOSTAT HYDROBROMIDE ingredient

Treatment: Method of treating epithelioid sarcoma

Dosage: TABLET;ORAL

Strength	Dosage	Availability
EQ 200MG BASE	TABLET;ORAL	Prescription

83. Drug name - TEMBEXA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8962829	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (12 years from now)
IN201627019468A	CHIMERIX	Morphic Forms Of Hexadecyloxypropyl Phosphonate Esters	Oct, 2034 (12 years from now)
IN328711B	CHIMERIX	A Method Of Preperation Of Morphic Forms Of Hexadecyloxyprop Yl-Phosphonate Esters	Oct, 2034 (12 years from now)
EP2999476A1	CHIMERIX	Morphic Forms Of Hexadecyloxypropyl-Phosphonate Esters	Oct, 2034 (12 years from now)
EP2999476A4	CHIMERIX	Morphic Forms Of Hexadecyloxypropyl-Phosphonate Esters	Oct, 2034 (12 years from now)
EP2999476B1	CHIMERIX	Morphic Forms Of Hexadecyloxypropyl-Phosphonate Esters	Oct, 2034 (12 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10112909	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (12 years from now)
US10487061	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (12 years from now)
US9371344	CHIMERIX	Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof	Oct, 2034 (12 years from now)

Drugs and Companies using BRINCIDOFOVIR ingredient

Treatment: Method of treating human smallpox disease

Dosage: TABLET;ORAL

Strength	Dosage	Availability
100MG	TABLET;ORAL	Prescription

84. Drug name - TRIJARDY XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10258637	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US11090323	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Apr, 2034 (11 years from now)
US9949998	BOEHRINGER INGELHEIM	Pharmaceutical composition, methods for treating and uses thereof	Jun, 2034 (11 years from now)

Drugs and Companies using EMPAGLIFLOZIN; LINAGLIPTIN; METFORMIN HYDROCHLORIDE ingredient

Treatment: Method of treating type 2 diabetes mellitus in a patient with renal impairment (45 ml/min/1.73 m2<=egfr<60 ml/min/1.73 m2) by once daily administration of 10 mg or 25 mg of empagliflozin in combination with linagliptin and metformin; Method of treating type 2 diabetes mellitus in a patient with renal impairment (egfr<60 ml/min/1.73 m2) by initiation of empagliflozin, linagliptin and metformin hcl if egfr>=45 ml/min/1.73 m2 and discontinuation if egfr <30 ml/min/1.73 m2

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
10MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
12.5MG;2.5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription
25MG;5MG;1GM	TABLET, EXTENDED RELEASE;ORAL	Prescription

85. Drug name - TRULANCE

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US10011637	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Jun, 2034 (11 years from now)
CN105764916B	SALIX	A Hyperpure Agonist Of Guanylate Cyclase C, Preparation And Use Method Of The Agonist	Jun, 2034 (11 years from now)
CN105764916A	SALIX	A Super-Pure Agonist Of Guanylate Cyclase C, Preparation And Using Method Of The Agonist	Jun, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11142549	SALIX	Ultra-pure agonists of guanylate cyclase C, method of making and using same	Jun, 2034 (11 years from now)

Drugs and Companies using PLECANATIDE ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
3MG	TABLET;ORAL	Prescription

86. Drug name - TRUSELTIQ

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11160804	HELSINN HLTHCARE	Pharmaceutical dosage forms	Dec, 2034 (12 years from now)
US10278969	HELSINN HLTHCARE	Pharmaceutical dosage forms	Dec, 2034 (12 years from now)

Drugs and Companies using INFIGRATINIB PHOSPHATE ingredient

Treatment: NA

Dosage: CAPSULE;ORAL

Strength	Dosage	Availability
25MG	CAPSULE;ORAL	Prescription
100MG	CAPSULE;ORAL	Prescription

87. Drug name - VELPHORO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10624855	VIFOR FRESENIUS	Pharmaceutical composition, comprising phosphate binder particles	Nov, 2034 (12 years from now)
US11234938	VIFOR FRESENIUS	Pharmaceutical composition, comprising phosphate binder particles	Nov, 2034 (12 years from now)

Drugs and Companies using FERRIC OXYHYDROXIDE ingredient

Treatment: NA

Dosage: TABLET, CHEWABLE;ORAL

Strength	Dosage	Availability
EQ 500MG IRON	TABLET, CHEWABLE;ORAL	Prescription

88. Drug name - VOGELXO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8785426	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (11 years from now)
US9662340	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (11 years from now)
US9295675	UPSHER SMITH LABS	Testosterone gel compositions and related methods	Feb, 2034 (11 years from now)

Drugs and Companies using TESTOSTERONE ingredient

Treatment: Method for transdermal delivery of testosterone

Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL

Strength	Dosage	Availability
12.5MG/1.25GM ACTUATION	GEL, METERED;TRANSDERMAL	Prescription
50MG/5GM PACKET	GEL;TRANSDERMAL	Prescription

89. Drug name - VOSEVI

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9296782	GILEAD SCIENCES INC	Inhibitors of hepatitis C virus	Jul, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11116783	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jan, 2034 (11 years from now)
US11116783 (Pediatric)	GILEAD SCIENCES INC	Combination formulation of two antiviral compounds	Jul, 2034 (11 years from now)

Drugs and Companies using SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR ingredient

Treatment: Treatment of adult patients with chronic hcv infection who have genotype 1, 2, 3, 4, 5, or 6 infection and have previously been treated with an hcv regimen containing an ns5a inhibitor; treatment of adult patients with chronic hcv infection who have genotype 1a or 3 infection and have previously been treated with an hcv regimen containing sofosbuvir without an ns5a inhibitor

Dosage: TABLET;ORAL

Strength	Dosage	Availability
400MG;100MG;100MG	TABLET;ORAL	Prescription

90. Drug name - VYXEOS

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10028912	CELATOR PHARMS	Method of lyophilizing liposomes	Sep, 2034 (12 years from now)

Drugs and Companies using CYTARABINE; DAUNORUBICIN ingredient

Treatment: Method of administering a reconstituted liposomal composition containing cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older; method of reconstituting a lyophilized liposomal composition for administering cytarabine and daunorubicin to treat newly-diagnosed therapy-related aml (t-aml) or aml with myelodysplasia-related changes (aml-mrc) in patients 1 year and older

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
100MG;44MG	POWDER;INTRAVENOUS	Prescription

91. Drug name - WELIREG

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9969689	MERCK SHARP DOHME	Aryl ethers and uses thereof	Sep, 2034 (11 years from now)
US9908845	MERCK SHARP DOHME	Aryl ethers and uses thereof	Sep, 2034 (11 years from now)
CN110372550B	MERCK SHARP DOHME	Aryl Ether And Use Thereof	Sep, 2034 (11 years from now)
CN110372550A	MERCK SHARP DOHME	Aryl Ether And Its Use	Sep, 2034 (11 years from now)
CN105530923B	MERCK SHARP DOHME	Aryl Ether And Its Use	Sep, 2034 (11 years from now)
CN105530923A	MERCK SHARP DOHME	Aryl Ether And Application	Sep, 2034 (11 years from now)
EP3043784A4	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)
EP3043784A1	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)
EP3417851B1	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)
EP3417852B1	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)
EP3417852A1	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)
EP3417851A1	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)
EP3043784B1	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)
EP3043784B9	MERCK SHARP DOHME	Aryl Ethers And Uses Thereof	Sep, 2034 (11 years from now)

Drugs and Companies using BELZUTIFAN ingredient

Treatment: NA

Dosage: TABLET;ORAL

Strength	Dosage	Availability
40MG	TABLET;ORAL	Prescription

92. Drug name - XARELTO

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9539218	JANSSEN PHARMS	Prevention and treatment of thromboembolic disorders	Feb, 2034 (11 years from now)
US9539218 (Pediatric)	JANSSEN PHARMS	Prevention and treatment of thromboembolic disorders	Aug, 2034 (11 years from now)

Drugs and Companies using RIVAROXABAN ingredient

Treatment: Treatment of pulmonary embolism with once daily, rapid-release tablet administered for at least five consecutive days; treatment of deep vein thrombosis with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism in patients undergoing knee or hip replacement surgery, with once daily, rapid-release tablet administered for at least five consecutive days; reduce the risk of stroke in patients with nonvalvular atrial fibrillation with once daily, rapid-release tablet administered for at least five consecutive days; prophylaxis of venous thromboembolism in acutely ill medical patients at risk for thromboembolic complications not at high risk of bleeding with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in the risk of recurrent dvt and/or pe in pediatric patients (>=50 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment; after completion of initial treatment lasting at least 6 months, to reduce the risk of recurrence of deep vein thrombosis and/or pulmonary embolism in certain patients with once daily, rapid-release tablet administered for at least 5 consecutive days; prophylaxis of pe, dvt and/or stroke in pediatric patients (>=50 kg) aged 2 years and older with congenital heart disease after fontan procedure with once daily, rapid-release tablet administered for at least 5 consecutive days; treatment of dvt and/or pe and reduction in risk of recurrent dvt and/or pe in pediatric patients (30-49.9 kg) once daily with rapid-release tablet administered for at least 5 consecutive days after at least 5 days parenteral anticoagulant treatment

Dosage: TABLET;ORAL

Strength	Dosage	Availability
2.5MG	TABLET;ORAL	Prescription
10MG	TABLET;ORAL	Prescription
15MG	TABLET;ORAL	Prescription
20MG	TABLET;ORAL	Prescription

93. Drug name - XEGLYZE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10292389	DR REDDYS LABS SA	Pediculicidal composition	Dec, 2034 (12 years from now)

Drugs and Companies using ABAMETAPIR ingredient

Treatment: Topical treatment of head lice infestation in patients 6 months of age and older

Dosage: LOTION;TOPICAL

Strength	Dosage	Availability
0.74%	LOTION;TOPICAL	Discontinued

94. Drug name - XELJANZ XR

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937181	PFIZER	Tofacitinib oral sustained release dosage forms	Mar, 2034 (11 years from now)
US10639309	PFIZER	Tofacitinib oral sustained release dosage forms	Mar, 2034 (11 years from now)

Drugs and Companies using TOFACITINIB CITRATE ingredient

Treatment: NA

Dosage: TABLET, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
EQ 11MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription
EQ 22MG BASE	TABLET, EXTENDED RELEASE;ORAL	Prescription

95. Drug name - XHANCE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10076614	OPTINOSE US INC	Nasal delivery devices	Oct, 2034 (12 years from now)

Drugs and Companies using FLUTICASONE PROPIONATE ingredient

Treatment: NA

Dosage: SPRAY, METERED;NASAL

Strength	Dosage	Availability
0.093MG	SPRAY, METERED;NASAL	Prescription

96. Drug name - XIPERE

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9937075	BAUSCH AND LOMB INC	Apparatus and methods for ocular injection	May, 2034 (11 years from now)

Drugs and Companies using TRIAMCINOLONE ACETONIDE ingredient

Treatment: NA

Dosage: SUSPENSION;INJECTION

Strength	Dosage	Availability
40MG/ML	SUSPENSION;INJECTION	Prescription

97. Drug name - XYOSTED (AUTOINJECTOR)

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10881798	ANTARES PHARMA INC	Needle assisted injection device having reduced trigger force	Feb, 2034 (11 years from now)
US11160751	ANTARES PHARMA INC	Hematocrit modulation through needle assisted jet injection of testosterone	Oct, 2034 (12 years from now)

Drugs and Companies using TESTOSTERONE ENANTHATE ingredient

Treatment: Method of administering testosterone enanthate subcutaneously

Dosage: SOLUTION;SUBCUTANEOUS

Strength	Dosage	Availability
50MG/0.5ML (50MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
75MG/0.5ML (75MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription
100MG/0.5ML (100MG/0.5ML)	SOLUTION;SUBCUTANEOUS	Prescription

98. Drug name - YONSA

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9889144	SUN PHARM	Abiraterone acetate formulation and methods of use	Mar, 2034 (11 years from now)
US10292990	SUN PHARM	Abiraterone steroid formulation	May, 2034 (11 years from now)

Drugs and Companies using ABIRATERONE ACETATE ingredient

Treatment: Use in combination with methylprednisolone for the treatment of patients with prostate cancer

Dosage: TABLET;ORAL

Strength	Dosage	Availability
125MG	TABLET;ORAL	Prescription

99. Drug name - ZERBAXA

Patent Number	Company	Patent Title	Patent Expiry
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8906898	CUBIST PHARMS LLC	Solid forms of ceftolozane	May, 2034 (11 years from now)
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10420841	CUBIST PHARMS LLC	Ceftolozane antibiotic compositions	Mar, 2034 (11 years from now)
US8968753	CUBIST PHARMS LLC	Ceftolozane-tazobactam pharmaceutical compositions	Mar, 2034 (11 years from now)
US9872906	CUBIST PHARMS LLC	Ceftolozane antibiotic compositions	Mar, 2034 (11 years from now)
US9320740	CUBIST PHARMS LLC	Ceftolozane-tazobactam pharmaceutical compositions	Mar, 2034 (11 years from now)
US10376496	CUBIST PHARMS LLC	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function	Sep, 2034 (11 years from now)
US10933053	CUBIST PHARMS LLC	Treating infections with ceftolozane/tazobactam in subjects having impaired renal function	Sep, 2034 (11 years from now)

Drugs and Companies using CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM ingredient

Treatment: Treatment of complicated urinary tract infection; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection, including pyelonephritis; treatment of complicated intra-abdominal infection; Treatment of complicated urinary tract infection in patients with end-stage renal disease on hemodialysis; treatment of complicated intra-abdominal infection in patients with end-stage renal disease on hemodialysis; Treatment of ventilator-associated bacterial pneumonia in patients with end-stage renal disease on hemodialysis; treatment of hospital-acquired bacterial pneumonia in patients with end-stage renal disease on hemodialysis

Dosage: POWDER;INTRAVENOUS

Strength	Dosage	Availability
EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	POWDER;INTRAVENOUS	Prescription

100. Drug name - ZOHYDRO ER

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9713611	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US9132096	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US9452163	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US10092559	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)
US9486451	RECRO GAINESVILLE	Abuse resistant pharmaceutical compositions	Sep, 2034 (11 years from now)

Drugs and Companies using HYDROCODONE BITARTRATE ingredient

Treatment: Treatment of pain

Dosage: CAPSULE, EXTENDED RELEASE;ORAL

Strength	Dosage	Availability
10MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
15MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
20MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
30MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
40MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued
50MG	CAPSULE, EXTENDED RELEASE;ORAL	Discontinued

101. Drug name - ZURAGARD

Patent Number	Company	Patent Title	Patent Expiry	Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10688291	ZUREX PHARMA	Medical skin applicator apparatus	Dec, 2034 (12 years from now)

Drugs and Companies using ISOPROPYL ALCOHOL ingredient

Treatment: Use as an antiseptic for the preparation of a patient's skin prior to surgery

Dosage: SOLUTION;TOPICAL

Strength	Dosage	Availability
70%	SOLUTION;TOPICAL	Discontinued

102. Drug name - ZYNRELEF KIT

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9592227	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US9913909	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US11253504	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US10398686	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)
US9744163	HERON THERAPS INC	Compositions of a polyorthoester and an aprotic solvent	Mar, 2034 (11 years from now)

Drugs and Companies using BUPIVACAINE; MELOXICAM ingredient

Treatment: Treatment of postsurgical pain providing analgesia to a patient for up to 72 hours, for example, after bunionectomy, open inguinal herniorrhaphy, or total knee arthroplasty via soft tissue or periarticular instillation

Dosage: SOLUTION, EXTENDED RELEASE;PERIARTICULAR

Strength	Dosage	Availability
60MG/2.3ML (29.25MG/ML);1.8MG/2.3ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription
200MG/7ML (29.25MG/ML);6MG/7ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription
300MG/10.5ML (29.25MG/ML);9MG/10.5ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription
400MG/14ML (29.25MG/ML);12MG/14ML (0.88MG/ML)	SOLUTION, EXTENDED RELEASE;PERIARTICULAR	Prescription

Pharsight

Drug Patents Expiring in 2034

1. Drug name - ABILIFY MAINTENA KIT

2. Drug name - ABRAXANE

3. Drug name - ADEMPAS

4. Drug name - AIRDUO DIGIHALER

5. Drug name - ALKINDI SPRINKLE

6. Drug name - ALUNBRIG

7. Drug name - ARIKAYCE KIT

8. Drug name - AUBAGIO

9. Drug name - AUSTEDO

10. Drug name - AYVAKIT

11. Drug name - BOSULIF

12. Drug name - BRUKINSA

13. Drug name - CAPLYTA

14. Drug name - CIBINQO

15. Drug name - CLENPIQ

16. Drug name - CONTRAVE

17. Drug name - COSELA

18. Drug name - COTELLIC

19. Drug name - DEXYCU KIT

20. Drug name - DIFICID

21. Drug name - DILAUDID

22. Drug name - DORYX

23. Drug name - DURYSTA

24. Drug name - EPCLUSA

25. Drug name - EPIDIOLEX

26. Drug name - EPINEPHRINE

27. Drug name - EVOMELA

28. Drug name - EVZIO

29. Drug name - EVZIO (AUTOINJECTOR)

30. Drug name - EXONDYS 51

31. Drug name - FIRDAPSE

32. Drug name - FULVESTRANT

33. Drug name - GANZYK-RTU

34. Drug name - GIAPREZA

35. Drug name - GIVLAARI

36. Drug name - GLYXAMBI

37. Drug name - GOCOVRI

38. Drug name - HARVONI

39. Drug name - HETLIOZ

40. Drug name - HETLIOZ LQ

41. Drug name - IBRANCE

42. Drug name - IDHIFA

43. Drug name - IMBRUVICA

44. Drug name - IMCIVREE

45. Drug name - INOMAX

46. Drug name - JADENU

47. Drug name - JARDIANCE

48. Drug name - JUBLIA

49. Drug name - KLOXXADO

50. Drug name - LEQVIO

51. Drug name - LILETTA

52. Drug name - LONSURF

53. Drug name - LOREEV XR

54. Drug name - LUZU

55. Drug name - MAKENA

56. Drug name - MAVYRET

57. Drug name - MORPHINE SULFATE

58. Drug name - NATESTO

59. Drug name - OMIDRIA

60. Drug name - ONZETRA XSAIL

61. Drug name - ORIAHNN (COPACKAGED)

62. Drug name - OTEZLA

63. Drug name - OXBRYTA

64. Drug name - OXLUMO

65. Drug name - PARSABIV

66. Drug name - PROCYSBI

67. Drug name - PROCYSBI

68. Drug name - RAYALDEE

69. Drug name - RESTASIS

70. Drug name - RHOPRESSA

71. Drug name - ROCKLATAN

72. Drug name - RYALTRIS

73. Drug name - RYBELSUS

74. Drug name - SINUVA

75. Drug name - SOOLANTRA

76. Drug name - SOTYLIZE

77. Drug name - SPINRAZA

78. Drug name - SPRITAM

availability in other generic markets.

Click on the highlighted region to filter.